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ABSTRACT
Background: Three subtypes of myeloproliferative neoplasms (MPNs): Polycythemia vera
(PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) showed overlapping
phenotype. There has been no specific cytogenetic marker identified in these subtypes. JAK2
gene has a critical role in the pathogenesis of MPNs. Similar mutation, namely JAK2 V617F
mutation, was found in PV, ET and PMF.
Objective :This study was done to define the prevalence of JAK2 V617F mutation in
Indonesian MPNs patients.
Methods : This is a cross-sectional study of 187 patients who were referred to Center for
Biomedical Research (CEBIOR) for JAK2 V617F mutation analysis. The study period was
November 2010 until November 2015. It was analysed using Amplification Refractory
Mutation System Polymerase Chain Reaction (ARMS-PCR) from peripheral blood vein.
Clinical data were secondary data retrieved from hospital medical records.
Results : The prevalence of JAK2 V617F mutation in Indonesian MPNs patients was 107 out
of 188 patients (56.92 %). Mutation prevalence distribution for each subtypes were 43 out of
70 (61.43 %) in PV, 25 out of 53 (47.17 %) in ET, 4 out of 6 (66.67 %) in PMF, whereas in
unspecified MPN/MPD/MDS 35 out of 59 (59.32 %).
Conclusion : The prevalence of JAK2 V617F mutation was found comparable with previous
studies in Indian MPNs. JAK2 V617F testing should be incorporated in the management
therapy of MPNs in Indonesia.
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INTRODUCTION
Myeloid malignancies are stem cell-derived and clonal
disorders, consist of three wide-ranging clinicopathologic
categories: acute myeloid leukemia (AML),
myelodysplastic syndrome (MDS) and myeloproliferative
neoplasm (MPNs). MPNs were first acknowledged by
William Damashek in 19511 The classic MPNs were
grouped into four subtypes, namely polycythemia vera
(PV), essential thrombocythemia (ET), primary
myelofibrosis (PMF) and chronic myelogenous leukemia
(CML).
They were initially grouped based on their common
phenotype of proliferation. Because of their similarities
in increasing mature peripheral blood cells and
overlapping phenotype, diagnosis has been difficult to
be established in the past. It was believed that it came
from similar unknown mechanism.1 The North
American Association of Central Cancer Registries
(NAACCR) stated that the age-adjusted incidence rate
was 2.1 per 100,000 in 2001-2003.2 For each disease
subtype, an earlier study in Sweden reported the annual
prevalence per 100,000 inhabitants for PV, ET, and
PMF were 2-2.8; 1.5; and 0.4 respectively.3,4
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The important issues in the course of MPNs are
thrombosis, hemorrhage, evolution to post-polycythemic
or post-thrombocythemic myelofibrosis and AML
transformation.2 Thrombosis and bleeding are the leading
causes of morbidity in MPNs.5 In one-third of MPNs
patients, early vascular events constitutes first disease
manifestation.6 Even though thrombosis is the most
frequent complication in MPNs, but bleeding is more
observed in ET.7
The understanding of the molecular pathogenesis of
myeloid malignancies has fundamentally derived from the
identification of t(9;22)(q34;q11) or Philadelphia
chromosome in CML. However, in many patients with
MPNs, no specific abnormality has been identified to
date. The frequency of cytogenetic abnormalities in the
Philadelphia-negative MPNs varies from approximately
40% in PMF to 3% in ET.8 The spectrum of aberrations is
heterogeneous, ranging from gains and losses of genetic
material to structural changes including unbalanced
translocations.9 The role of cytogenetic abnormalities as a
prognostic marker in PMF has been suggested, both at the
time of diagnosis and later during disease course.10
In molecular level, Philadelphia chromosome is
derived from two genes fusion, BCR-ABL on the 22q-
and the reciprocal ABL-BCR on 9q-, resulting a chimeric
gene BCR-ABL. The identification of the BCR-ABL
gene and consequent protein led to the production of
small-molecule drugs, proposed to hinder BCR-ABL
tyrosine kinase activation by competitive binding at the
ATP-binding site: Imatinib mesylate (IM).11 IM turn out
to be the first drug of choice in chronic phase CML, as a
result of its high efficacy, low toxicity and capacity to
preserve strong hematological and cytogenetic
responses.11
Several recent discoveries have identified a central
role of protein tyrosine kinase (PTK) in the pathogenesis
of MPNs. Several groups reported the discovery of JAK2
V617F mutation in early 2005.12-14 Baxter et al (2005)
found a single base substitution, guanine to thymine
change at 1849, which resulted in the change of valine to
phenylalanine in exon 14 of the pseudokinase domain of
tyrosine kinase JAK2 (Janus Kinase 2) gene in 97% PV,
57% ET and 50% PMF.12 This mutation results in a gain
of function due to the constitutive activation of tyrosine
kinase-dependent cellular signaling pathways, particularly
of the JAK-STAT (Signal Transducers and Activators of
Transcription) . The pathway is principal in regulation
of cell proliferation, differentiation and apoptosis in .14
JAK2 V617F mutation as a common genetic
abnormality in PV, ET, and PMF had pointed the
possibility of using tyrosine kinase as a valid therapy
target. The use of drug that targets the tyrosine kinases is
expected to follow the efficacy of IM and other tyrosine
kinase inhibitors in CML.2,7
MPNs patients who carried JAK2 V617F mutation
have been associated with older age at diagnosis (ET and
PMF),15 higher hemoglobin level (ET and PMF),16
leukocytosis (ET and PMF),15 lower platelet count (ET),
larger spleen size (PV, ET and PMF),17 the need for
spelenectomy,17 and leukemic transformation17. Patients
with mutation have been associated with shorter survival
in PMF, but less likely to require blood transfusion.18
Dunlap et al studied the correlation between
cytogenetic abnormalities with disease stage
and JAK2 V617F status in MPNs and MDS/MPNs
patients. Cytogenetic data were available in ninety-seven
out of 179 cases (54,19%). JAK2 V617F positive group
showed higher frequency of chromosomal abnormalities
(51% vs. 27%). In JAK2 V617F positive group, the
commonest abnormalities were found in chromosome 9,
chromosome 7, chromosome 20q, while 13q and trisomy
21 were frequent in JAK2 V617F negative group.
Chromosome 7 and complex abnormalities were
associated with blastic transformation.19
This study aim was to define the prevalence of JAK2
V617F mutation in Semarang MPNs patients.
METHODS
This is a cross-sectional study of 187 patients who
were referred to Center for Biomedical Research
(CEBIOR) for JAK2 V617F mutation analysis.
Myeloproliferative neoplasm's consisted of PV, ET,
PMF and/or MPNs unclassified subtypes. The diagnosis
was determined by the reffering clinician according to
clinical symptoms and signs, and other supporting data.
The study period was November 2010 until November
2015.
DNA was extracted from peripheral blood using the
salting out method at the Center for Biomedical
Research (CEBIOR) Faculty of Medicine, Diponegoro
University (FMDU). JAK2 V617F mutation was
obtained using the Amplification Refractory Mutation
System (ARMS-PCR) according to Baxter et al with
some minor modifications.12 The principle of the method
is using one common reverse primer and two forward
primers. One forward primer would be specifically
paired to the mutant JAK2 (if the patient carry the
mutation) and the other forward primer would be paired
with the wild-type (if the patient did not carry the
mutation). The third base from 3’ end was intentionally
mismatched to maximize the allele specificity. The
appearance of two bands at 364 bp and 203 bp is
determined as positive, and single band at 364 bp as
negative. The 364 bp band also acted as internal control
for every sample (See Figure 1). DNA Sequencing to
ascertain the presence of G to T nucleotide substitution
at position 1849 was done in The Agency for The
Assessment and Application of Technology/Badan
Pengkajian dan Penerapan (BPPT) in Jakarta (See
Figure 2).
Patient’s clinical data, the result of routine
hematology examination, bone marrow smear analysis,
and/or relevant findings were retrieved from hospital
medical record and summarized in a case report form for
each subject.
The data were tested for mutation status difference
in proportions using chi-square test. Unpaired t-test was
used to compare continuous variables between JAK2
V617F positive and negative groups such as age, and
blood count, except for leukocytes.
The ethical clearance was approved by the Health
Research Ethical Committee of MFDU/Dr. Kariadi
Hospital, Semarang and Dr. Kariadi Hospital Research
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Review Board. Study subjects were provided with
informed consent.
RESULTS
During the study period, there were 188 patients from
around Central Java who were referred for JAK2 V617F
mutation. (Table 1). There were 59 patients who were
diagnosed as unspecified MPNs, myeloproliferative
disease (MPD) or myelodysplastic syndrome (MDS),
while there were 70 patients who were diagnosed as PV or
having high hemoglobin level, 53 patients diagnosed as
ET or showing thrombocytosis, and 6 diagnosed as
myelofibrosis (See Table 1). Among the four groups, only
the ET/Thrombocytosis group showed lower proportion of
JAK2 V617F-positive mutation.
Table 1. Referral diagnosis for JAK2 V617F analysis
Other than diagnosis in MPNs, several of the study
subjects had other diagnosis in hematology or vascular
disease (See Table 2). These conditions showed a
possibility that they also experienced vascular events,
especially thrombosis that was related to their MPNs
diagnosis and JAK2 V617F mutational status. Diagnosis
involving other systems showed that elevation of blood
count (in PV and ET) might be an incidental finding that
was found during the diagnosis work-up, not solely
derived from symptoms and signs of MPNs
Table 2. Accompanying hematology and/or vascular event
(thrombosis) diagnosis
Table 3. Accompanying diagnosis involving other
systems
Table 4 showed that positive cases were older than
negative cases (54.43 ±11.857 vs. 49.01 ±16.351),
although it was insignificant. In both sex groups, more
positive cases were observed in the study subjects.
Blood count at diagnosis showed that positive cases had
higher hemoglobin and hematocrite values. In the
contrary, leukocyte and platelet counts were lower in
positive group. Four JAK2 V617F mutation positive
subjects (3 PV and 1 ET) was confirmed with
sequencing, and showed the present of G to T nucleotide
substitution (Figure 2).
Table 4. Demographic characteristics
Table 5. Blood count
Comparison was tested using unpaired t-test, except for leukocyte
(Fischer’s exact test)
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Figure 1. JAK2 V617F mutation detection using ARMS-
PCR. Lane 1 to 5 represented subjects number 12/F/11 to
16/F/11). Upper band at 364 bp were the internal PCR
control which appeared in every sample tested. Lower
band at 203 bp indicated the presence of mutation.
Positive control (PC) was the positive result from
previous PCR, negative control (NC) came from non-
MPNs individual, (B) is blank, (M) 100 bp marker ladder.
Figure 2. Sequencing profile of a subject (07/F/11) whose
PCR positive for JAK2 V617F mutation using forward
primer. Arrow indicated the presence of mutation
c.1849G>T in exon 14 of JAK2 gene.
DISCUSSION
This study results supported the fact that JAK2 V617F
mutations were found in majority of MPNs patients
(56.92 %). A study in India reported 68% of MPNs
patients harbored this mutation.20 The distribution of
JAK2 V617F mutation in the disease subtypes were
similar with other reports in Caucasian,12,13,17 except for
PV. This was possibly caused by different cut-off point
that has been used by reffering clinicians.
Although the routine blood count values were not
significantly different between the two groups, the profile
that was observed in our findings was similar with other
studies. The conclusion of a meta-analysis measuring the
effect of JAK2 V617F on thrombotic risk in 492 studies
suggested that JAK2 V617F-positive patients were older
at diagnosis, had higher hemoglobin, but lower
thrombocyte counts.21 The most possible mechanism
underlying these observations was that JAK2 V617F
mutation caused hypersensitivity to cytokine
stimulation.13
A study which correlated JAK2 mutation status,
hemostatic risk factors and thrombophilic factors in ET
patients stated that JAK2 V617F mutation have been
associated with older age at diagnosis (ET and PMF),15
higher hemoglobin level (ET and PMF),16 leukocytosis
(ET and PMF),15 lower platelet count (ET)17. In
addition, JAK2 V617F mutational status predicts
progression to large splenomegaly and leukemic
transformation in primary myelofibrosis in PV, ET and
PMF. 17 Shorter survival in PMF patients have been
associated with the JAK2 V617F mutation, but less
likely to require blood transfusion.18 High proportion of
JAK2 V617F mutation which was found in our study
subjects should be carefully followed-up by the reffering
clinicians, in concern of the disease course related to
positive results.
Among patients with hemoglobin level above normal
cut-offs, the presence of JAK2 V617F mutation allows
the diagnosis of PV in >95% cases. Less than 2% of
these patients might carry JAK2 exon 12 mutations.22
Further study should elucidate the presence of other
JAK2 mutations in JAK2 V617F negative patients.
The demonstration of JAK2 V617F mutation in
patients with thrombocyte count < 600.000/dL
(according to 2001 WHO classification system),23
supported the use of lower cut-off of thrombocyte count
for ET diagnosis in the 2008 revision (changed to >
450.000/dL) and might help the exclusion of reactive
thrombocytosis.16,24 However, JAK2 V617F mutation
was found only in 47.17% ET and 66.67% PMF cases.
Thus, bone marrow smear analysis remains as an
important diagnosis tool of ET, since bone marrow
appearance in ET patients is distinct from typical PV or
PMF, and vice versa for PMF.25
The use of peripheral blood, as in our study, has been
reported as objective and made the JAK2 mutations
screening become more accessible and practical in order
to study patients suspected having MPNs, compare to
invasive test like bone marrow examination or expertise-
dependent test such as direct red cell mass
measurement.28 However, this molecular testing alone
could not outweigh the important baseline information
yielded from bone marrow histology and cytogenetic
analysis.
Results of studies in familial MPNs about
increased risk of first-degree relatives might
improve the information that the JAK2 V617F
testing should be provided for families of MPNs
patients.
However, there were some limitations of the study.
First, only JAK2 V617F mutation was studied. Despite
the fact that the mutation is the commonest in MPNs, a
large number of other mutations have been discovered
and it has not been understood yet how is the hierarchy
in this genetic complexity of MPNs. Second, the
diagnosis of MPNs subtypes was made without
incorporating red cell mass, serum Epo level or EEC
(the complete 2008 WHO diagnostic criteria) although
the remaining criteria were sufficient to establish the
diagnosis. Third, the research setting was at only one
center, given that the prevalence of MPNs is 2,1 per
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100.000 individuals a multicenter study might yield
higher number of participants.2
CONCLUSION
Supported by the high incidence of JAK2 V617F
mutation in our results, which were comparable with
studies for in Indian and Caucasian we would recommend
the integration of JAK2 V617F mutation testing in the
diagnosis and management of MPNs cases in Indonesia.
SUGGESTIONS
Further studies should be conducted to explore
the association of cytogenetic and JAK2 V617F
mutation, clinical profiles, complications and
prognosis in MPNs. As well as the exploration of
other mutations that involved in the pathogenesis of
MPNs. The main goal of the follow-up studies are to
establish JAK2 inhibitors for JAK2 V617F-positive
patients in clinical practice.
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